NEWS

Start each day with OncologySTAT’s premier medical and pharmaceutical news provided by Elsevier Global Medical News and FDC Reports.

Page 1 of 350

« start ‹ previous ... 1 2 3 4 5 ... next › end »

Docs Need Primer on Long-Term Effects of Chemotherapy

P Wendling, 2012 May 17, Elsevier Global Medical News

Many primary care physicians - and even some oncologists - are unaware of common long-term side effects of four widely used breast and colorectal cancer drugs, a national survey by the National Cancer...

In the Pipeline: BRAF-Plus-MEK Inhibition Slows Melanoma

P Wendling, 2012 May 17, Elsevier Global Medical News

Combining the BRAF inhibitor dabrafenib with the MEK inhibitor trametinib dramatically delays metastatic melanoma progression without the skin toxicities associated with vemurafenib therapy.Median progression-free...

Crizotinib Shows Strong Activity Against ALK-Driven Pediatric Cancers

K Wachter, 2012 May 17, Elsevier Global Medical News

The recently approved cancer drug crizotinib draws strong responses in children whose cancers have mutations in the gene targeted by the drug, according to early data from a phase I dose-escalating study.The...

NICE Reverses Course on Abiraterone

J Smith, 2012 May 16, Elsevier Global Medical News

After initially turning it down - and being pressured to reevaluate by the U.K. Department of Health - the clinical effectiveness agency for England and Wales has decided to recommend abiraterone, in combination...

Scleroderma Malignancy Risk Linked to Antinuclear Antibodies

S Freeman, 2012 May 16, Elsevier Global Medical News

GLASGOW, SCOTLAND (EGMN) - The presence of specific autoantibodies may help to predict which patients with systemic sclerosis are likely to develop cancer within a few years of their diagnosis, according...

Olanzapine Overcomes Chemotherapy-Induced Vomiting and Nausea

K Wachter, 2012 May 16, Elsevier Global Medical News

The antipsychotic olanzapine trounced standard therapy for breakthrough chemotherapy-induced nausea and vomiting in a clinical trial that could change the way some cancer patients are treated.In the double-blind...

Neoadjuvant Abiraterone Helps Clear Aggressive, Early-Stage Prostate Tumors

P Wendling, 2012 May 16, Elsevier Global Medical News

Neoadjuvant abiraterone helped clear tumors in one-third of men with localized, high-risk prostate cancer in an ongoing randomized phase II trial, investigators report.At 6 months, a pathological complete...

Linking EHRs to Cancer Registries Good in Theory, But Difficult in Practice, ASCO Says

G Twachtman, 2012 May 14, The Pink Sheet Daily

The American Society of Clinical Oncology is questioning whether electronic health records are ready to meet a proposed meaningful use option that would have EHRs communicating with cancer registries,...

Fatty Acids in Fish May Lower Liver Cancer Risk

MA Moon, 2012 May 11, Elsevier Global Medical News

The consumption of fish rich in n-3 polyunsaturated fatty acids was inversely related to the risk of developing hepatocellular carcinoma in a population-based study of Japanese adults, Dr. Norie Sawada...

NICE Rules Out Sanofi’s Jevtana on Grounds of Cost Effectiveness

F Kermani, 2012 May 10, The Pink Sheet Daily

Sanofi's prostate cancer therapy Jevtana (cabazitaxel) has once again, and for the final time, been rejected by England’s National Institute for Health and Clinical Excellence in a decision that alludes...